Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Developmental and epileptic encephalopathies (DEEs) include EEG abnormalities, developmental delays, and early-onset epilepsy are the hallmarks of severe illnesses. These disorders are frequently brought on by genetic abnormalities that alter brain anatomy, synaptic transmission, or neuronal signaling. Dravet syndrome and West syndrome are examples of DEEs, in which seizures exacerbate developmental deficits. Surgery, antiepileptic medications, ketogenic diets, and precision medicine are all used in treatment. DEEs have a dismal prognosis and are frequently resistant to conventional treatments, even with interventions. The Developmental and Epileptic Encephalopathy pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Q1 2026 Market Updates
Overview: The Developmental And Epileptic Encephalopathy Pipeline Insight market entered Q1 2026 on a familiar trajectory and exited it having absorbed the full force of the Iran-US-Israel conflict. Demand and supply chain dynamics for the global developmental and epileptic encephalopathy pipeline insight market. Energy infrastructure investment acceleration, driven by the need to substitute for QatarEnergy supply disruption following QatarEnergy force majeure declared following Ras Laffan drone strikes on March 2, 2026 and to maximize production at Brent crude at USD 126/barrel (Wikipedia), stepped-up procurement of oil and gas pipeline, process piping, and hydraulic system components. LNG terminal construction and expansion programs generated lifted demand for cryogenic, high-pressure, and specialty piping systems. Construction activity supported by defense facility programs and infrastructure investment maintained water, drain, and plumbing system procurement across the building sector.
United States: The domestic US picture in Q1 2026 was shaped by Across the United States, US developmental and epileptic encephalopathy pipeline insight market demand through Q1 2026 was driven by energy infrastructure investment, with LNG terminal expansion and oil and gas production maximization generating stepped-up procurement of line pipe, process piping, and flow control components for new and upgraded energy infrastructure. US residential and commercial construction activity, supported by infrastructure investment programs and defense facility development, maintained plumbing, drain, and water supply piping demand. US water and wastewater utility infrastructure investment, elevated by Q1 2026 resilience priorities, generated demand for water main pipe replacement and treatment facility piping upgrades. Polymer and PVC pipe manufacturers, Nexeo, Charlotte Pipe, and Georg Fischer, navigated elevated resin costs from petrochemical feedstock price increases linked to Brent crude at USD 126/barrel (Wikipedia).
Iran & Israel: Gulf state oil and gas pipeline and process piping investment, with Saudi Aramco, ADNOC, and QatarEnergy maximizing production and expanding facility capacity during Q1 2026, generated stepped-up procurement of high-specification line pipe, process piping, and flow control components across major producing regions. Israel's water infrastructure, including the National Water Carrier pipeline network and desalination plant piping systems, maintained priority investment in pipe replacement, leak detection, and resilience upgrades throughout Q1 2026 as water security is a national strategic priority. Iranian oil and gas pipeline and process piping infrastructure, subject to Q1 2026 strikes on energy and industrial facilities, sustained damage across conflict-affected provinces, compounding existing deterioration from sanctions-limited maintenance and pipe replacement access.
Key Takeaways
Government & Policy Watch
- LNG infrastructure demand: US and global LNG terminal expansion, accelerated by QatarEnergy supply disruption, is driving stepped-up procurement of cryogenic, high-pressure, and process piping systems for terminal construction and expansion.
- Oil and gas pipeline investment: US and GCC oil and gas pipeline and facility expansion, driven by high commodity prices, is generating procurement demand for line pipe, process piping, and flow control components across energy infrastructure.
- Water infrastructure resilience: US and allied-nation water utility infrastructure investment, elevated by Q1 2026 resilience priorities, is driving pipe replacement and treatment facility piping upgrade programs.
Market & Industry Impact
- Market growth: The developmental and epileptic encephalopathy pipeline insight market is growing on energy infrastructure expansion, water utility investment, residential and commercial construction, and industrial facility development, with Q1 2026 energy investment providing near-term demand acceleration.
- Polymer pipe growth: PVC, PE, and CPVC piping systems, offering corrosion resistance, lighter weight, and lower installation cost versus metal alternatives, are one of the faster-growing pipe categories across water, drainage, and process applications.
- Smart piping: Intelligent pigging, sensor-embedded pipe systems, and IoT-connected leak detection are growing in adoption for oil and gas and water utility pipeline management, driven by asset integrity and regulatory compliance requirements.
Procurement & Supply Chain Alert
- Resin cost exposure: PVC and PE pipe manufacturing depends on petroleum-derived polymer resins, with Q1 2026 energy price increases elevating feedstock costs and compressing pipe manufacturer margins.
- Steel pipe supply: Steel line pipe supply is affected by global steel market conditions and Q1 2026 supply chain disruption, with mill lead times extending as energy infrastructure investment creates lifted demand across steel pipe categories.
- Installation constraints: Pipeline construction and piping installation require certified welders, pipefitters, and specialized heavy equipment, workforce and equipment availability constraints that limit project execution speed.
-
Major companies involved in the developmental and epileptic encephalopathy pipeline analysis include Neurocrine Biosciences, and Takeda among others.
-
Leading drugs currently in the pipeline include NBI-921352, and REGN5381, others.
-
Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
Report Coverage
The Developmental and Epileptic Encephalopathy Pipeline Analysis Report by Expert Market Research gives comprehensive insights into developmental and epileptic encephalopathy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Developmental and Epileptic Encephalopathy therapeutics. The developmental and epileptic encephalopathy report assessment includes the analysis of over 50 pipeline drugs and 25+ companies. The developmental and epileptic encephalopathy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with developmental and epileptic encephalopathy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to developmental and epileptic encephalopathy.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Developmental and Epileptic Encephalopathy Pipeline Outlook
Genetic abnormalities affecting ion channels, synaptic proteins, and neuronal signaling pathways are part of the pathophysiology of developmental and epileptic encephalopathy (DEE). These disturbances impede synaptic transmission, plasticity, and neuronal excitability by causing aberrant cortical and subcortical connections. Defects in metabolism or structural brain abnormalities may also be involved. By changing intracortical connections throughout crucial developmental stages, the ensuing epileptiform activity intensifies cognitive delays, leading to extensive cortical dysfunction and serious neurodevelopmental abnormalities.
Developmental and epileptic encephalopathy (DEE) is treated using a variety of strategies depending on the type of seizure and its underlying cause. Anti-seizure drugs are common tactics, however, many DEEs are resistant to drugs. Vagus nerve stimulation (VNS), ketogenic diets, and surgical procedures for focal seizures are alternatives. Emerging alternatives include gene-targeted medicines, repurposed medications like fenfluramine, and precision therapeutics like cannabidiol. These seek to enhance general quality of life and seizure control.
Developmental and Epileptic Encephalopathy Epidemiology
Each illness and population has a different prevalence of developmental and epileptic encephalopathy (DEE). DEE has a cumulative incidence of 169 per 100,000 children with infantile epileptic spasms syndrome is the most prevalent at 58.2 per 100,000 children. Other syndromes such as Lennox-Gastaut syndrome and epilepsy with myoclonic-atonic seizures are less common. Genetic factors that contribute significantly to the prevalence of DEE include mutations in SCN1A and CDKL5.
Developmental and Epileptic Encephalopathy – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of developmental and epileptic encephalopathy drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Small molecule
- Peptides
- Gene Therapy
- Biologics
By Route of Administration
- Oral
- Parenteral
- Others
Developmental and Epileptic Encephalopathy – Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total developmental and epileptic encephalopathy clinical trials.
In the developmental and epileptic encephalopathy pipeline, majority of the candidates are in Phase II demonstrating progress toward potential treatments.
Developmental and Epileptic Encephalopathy – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the developmental and epileptic encephalopathy pipeline analysis include monoclonal antibody, peptides, small molecule and gene therapy. The developmental and epileptic encephalopathy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Developmental and Epileptic Encephalopathy.
Developmental and Epileptic Encephalopathy Clinical Trials – Key Players
The EMR report for the developmental and epileptic encephalopathy pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in developmental and epileptic encephalopathy clinical trials:
- Neurocrine Biosciences
- Takeda
Developmental and Epileptic Encephalopathy – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for developmental and epileptic encephalopathy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of developmental and epileptic encephalopathy drug candidates.
Drug: NBI-921352
NBI-921352, developed by Neurocrine Biosciences, is an investigational selective NaV1.6 inhibitor aimed at treating SCN8A developmental and epileptic encephalopathy (SCN8A-DEE), a rare and severe form of epilepsy. A Phase 2 randomized, double-blind, placebo-controlled study is underway to assess its efficacy, safety, and pharmacokinetics as adjunctive therapy in patients aged 2 to 21 with SCN8A-DEE. The trial began in January 2022 and is expected to complete by December 2025.
Drug: Soticlestat
Soticlestat, developed by Takeda, is an investigational, first-in-class inhibitor of cholesterol 24-hydroxylase (CH24H). It is an enzyme primarily expressed in the brain that catabolizes cholesterol to 24-S hydroxycholesterol (24HC), resulting in a reduction in glutamatergic hyperexcitability. In the Phase 2 ELEKTRA study, soticlestat achieved its primary endpoint, demonstrating a statistically significant reduction in seizure frequency in children with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS).
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Developmental and Epileptic Encephalopathy Pipeline Analysis Report
- Which companies/institutions are leading the developmental and epileptic encephalopathy drug development?
- What is the efficacy and safety profile of developmental and epileptic encephalopathy pipeline drugs?
- Which company is leading the developmental and epileptic encephalopathy pipeline development activities?
- What is the current developmental and epileptic encephalopathy commercial assessment?
- What are the opportunities and challenges present in the developmental and epileptic encephalopathy pipeline landscape?
- Which company is conducting major trials for developmental and epileptic encephalopathy drugs?
- Which companies/institutions are involved in developmental and epileptic encephalopathy collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in developmental and epileptic encephalopathy?
Reasons To Buy This Report
The Developmental and Epileptic Encephalopathy Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for Developmental and Epileptic Encephalopathy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into developmental and epileptic encephalopathy collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share